and the National Institutes of Health Office of Rare Diseases present the
Biospecimen Research Network (BRN) Symposium:
Renaissance M Street Hotel
Washington, D.C.
Agenda
Symposium Goal:The primary goal of the symposium is to address the significant impact of pre-analytical biospecimen variability on cancer research and molecular medicine.
The meeting will feature expert presentations and interactive discussions from a broad range of stakeholders whose work involves biospecimens, including research investigators, clinicians, industry representatives, hospital administrators and patient advocates.
| Thursday, March 13, 2008 | |||
| 7:30 a.m. - 8:30 a.m. | Registration and Continental Breakfast | ||
| 8:30 a.m. - 8:45 a.m. | Welcome Anna D. Barker, Ph.D. Deputy Director National Cancer Institute (NCI) Director Advanced Technologies and Strategic Partnerships |
||
| 8:45 a.m. - 9:15 a.m. | The Importance of High-Quality Biospecimens to the Research Enterprise PDF Document: 1.63 MBCarolyn C. Compton, M.D., Ph.D. Director, Office of Biorepositories and Biospecimen Research (OBBR) Acting Director, Office of Technology and Industrial Relations (OTIR) Office of the Director, NCI |
||
| 9:15 a.m. - 9:30 a.m. | Question-and-Answer Session | ||
| 9:30 a.m. - 10:00 a.m. | The Role of Biospecimens in Biomarker Research: Challenges and Opportunities PDF Document: 1.74 MB David F. Ransohoff, M.D. Professor of Medicine and Clinical Professor of Epidemiology University of North Carolina at Chapel Hill |
||
| 10:00 a.m. - 10:15 a.m. | Question-and-Answer Session | ||
| 10:15 a.m. - 10:30 a.m. | Break | ||
| 10:30 a.m. - 12 noon | Lessons Learned: Effects of Biospecimen Quality on Genomic and Proteomic Research
|
||
| 10:30 a.m. - 11:00 a.m. | Pitfalls and Gaps in Research Using Human Biospecimens |
||
| 11:00 a.m. - 11:15 a.m. | Question-and-Answer Session |
||
| 11:15 a.m. - 11:45 a.m. | Critical Pre-Analytical Variables in the Real World of Tissue Procurement |
||
| 11:45 a.m. - 12 noon | Question-and-Answer Session |
||
| 12 noon - 1:15 p.m. | Hosted Lunch Tables: Meet the Experts (Lunch will be available for purchase.) |
||
| 1:15 p.m. - 2:45 p.m. | HER2/neu: Lessons Learned From Paired Diagnostics and Therapeutics
|
||
Presentations and Panel Discussion: |
|||
| 1:15 p.m. - 1:35 p.m. | Paul Waring, M.D., Ph.D., M.B.B.S. |
||
| 1:35 p.m. - 1:55 p.m. | Measurement of HER2 |
||
| 1:55 p.m. - 2:15 p.m. | Molecular Diversity of Human Breast Cancers |
||
| 2:15 p.m. - 2:45 p.m. | Panel Discussion |
||
| 2:45 p.m. - 3:00 p.m. | Break | ||
| 3:00 p.m. - 5:00 p.m. | Research Advances in Biospecimen Science I
|
||
| 3:00 p.m. - 3:20 p.m. | The NCI Biospecimen Research Network and Literature Database |
||
| 3:20 p.m. - 3:30 p.m. | Question-and-Answer Session |
||
| 3:30 p.m. - 3:50 p.m. | Influence of Cellular Heterogeneity in Carcinoma Specimens for Identification of Clinically Relevant Molecular Signatures |
||
| 3:50 p.m. - 4:00 p.m. | Question-and-Answer Session |
||
| 4:00 p.m. - 4:20 p.m. | Effects of Fixation vs. Tissue Processing on Immunohistochemical Analysis |
||
| 4:20 p.m. - 4:30 p.m. | Question-and-Answer Session |
||
| 4:30 p.m. - 4:50 p.m. | Proteomic Discovery in Archived Tissue Blocks |
||
| 4:50 p.m. - 5:00 p.m. | Question-and-Answer Session |
||
| 5:00 p.m. - 5:15 p.m. | Day 1 Wrap-Up Carolyn C. Compton, M.D., Ph.D. Director, OBBR Acting Director, OTIR Office of the Director, NCI |
||
| 5:15 p.m. - 7:00 p.m. | Poster Session and Reception Poster presenters may begin to set up their posters starting at 4:00 p.m. |
||
| Friday, March 14, 2008 | |||
| 7:30 a.m. - 8:30 a.m. | Registration and Continental Breakfast | ||
| 8:30 a.m. - 9:00 a.m. | Locking in Pre-Analytical and Post-Analytical Performance: Being Pound Wise, Not Penny Foolish PDF Document: 46 KB Steve Gutman, M.D. Director Office of In Vitro Diagnostic Device Evaluation and Safety (OVID) Center for Devices and Radiological Health Food and Drug Administration (FDA) |
||
| 9:00 a.m. - 9:15 a.m. | Question-and-Answer Session | ||
| 9:15 a.m. - 9:35 a.m. | Patients' Perspective on Biospecimen Quality PDF Document: 492 KB Paula Kim Chief Executive Officer Translating Research Across Communities |
||
| 9:35 a.m. - 9:45 a.m. | Question-and-Answer Session | ||
| 9:45 a.m. - 10:00 a.m. | Break | ||
| 10:00 a.m. - 11:30 a.m. | Assessing and Qualifying Biospecimen Quality
|
||
| 10:00 a.m. - 10:20 a.m. | Signal:Noise? The Importance of the Pre-Analytical Phase in Sample Storage |
||
| 10:20 a.m. - 10:30 a.m. | Question-and-Answer Session |
||
| 10:30 a.m. - 10:50 a.m. | Pre-Analytical Variables in Validation of Methylated Biomarkers in Blood Plasma |
||
| 10:50 a.m. - 11:00 a.m. | Question-and-Answer Session |
||
| 11:00 a.m. - 11:20 a.m. | Measuring Biomarker Stability in Frozen Tissue |
||
| 11:20 a.m. - 11:30 a.m. | Question-and-Answer Session |
||
| 11:30 a.m. - 12:30 p.m. | Lunch (Lunch will be available for purchase.) |
||
| 12:30 p.m. - 2:00 p.m. | Research Advances in Biospecimen Science II
|
||
| 12:30 p.m. - 12:50 p.m. | Overcoming Challenges to Tissue-Based Studies |
||
| 12:50 p.m. - 1:00 p.m. | Question-and-Answer Session |
||
| 1:00 p.m. - 1:20 p.m. | Nonpatient-Related Variables Affecting Detection of VEGF in Urine Biospecimens |
||
| 1:20 p.m. - 1:30 p.m. | Question-and-Answer Session |
||
| 1:30 p.m. - 1:50 p.m. | Defining Optimal Tissue Handling Procedures for Multiplex In Vitro Diagnostics |
||
| 1:50 p.m. - 2:00 p.m. | Question-and-Answer Session |
||
| 2:00 p.m. - 2:15 p.m. | Break | ||
| 2:15 p.m. - 3:45 p.m. | Incorporating Biospecimen Science Into Research Practice: Opportunities, Challenges, and Progress
|
||
| 2:15 p.m. - 2:35 p.m. | Harmonizing Biospecimen Best Practices Across the Prostate SPORES |
||
| 2:35 p.m. - 2:45 p.m. | Question-and-Answer Session |
||
| 2:45 p.m. - 3:05 p.m. | Practical Applications of Biospecimen Science in Biobanking |
||
| 3:05 p.m. - 3:15 p.m. | Question-and-Answer Session |
||
| 3:15 p.m. - 3:35 p.m. | CAP: Preparing Pathologists |
||
| 3:35 p.m. - 3:45 p.m. | Question-and-Answer Session |
||
| 3:45 p.m. - 4:15 p.m. | General Question-and-Answer Session | ||
| 4:15 p.m. - 4:30 p.m. | Closing Remarks Carolyn C. Compton, M.D., Ph.D. Director, OBBR Acting Director, OTIR Office of the Director, NCI |
||
Back to Top
